EUCTR2019-002430-36-DE进行中（未招募）1 期
A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by on-demand selective TACE (sdTACE) upon detection of disease progression or of initial synchronous treatment with TACE and Atezo/Bev on objective response rate in the treatment of unresectable hepatocellular carcinoma patients (DEMAND) - DEMAND
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 106
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patient’s signed informed consent
- •2.Age = 18 years at time of signing Informed Consent Form
- •3.Ability to comply with the study protocol, according to investigator's judgement
- •4.Life expectancy of at least 12 weeks
- •5.HCC with histologically confirmed diagnosis
- •6.Disease that is not amenable to curative surgical and/or local ablation treatment according to consensus resolution of the multidisciplinary tumor board of the trial center but eligible for TACE, with tumor burden below 50% of liver volume.
- •7.At least one measurable (per RECIST 1.1) untreated lesion
- •8.ECOG Performance Status of 0 or 1
- •9.Child-Pugh class A or B7
- •10.Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to randomization, unless otherwise specified:
- •–ANC =1.5 x 109/L (1500/µL) without granulocyte colony-stimulating factor support
- •–Lymphocyte count = 0.5 x 109/L (500/µL)
- •–Platelet count = 75 x109/L (75,000/µL) without transfusion
- •–Hemoglobin = 90 g/L (9 g/dL); patients may be transfused to meet this criterion.
- •–AST, ALT, and alkaline phosphatase = 5 x upper limit of normal (ULN)
- •–Serum bilirubin = 3 x ULN
- •–Serum creatinine = 1.5 x ULN or creatinine clearance = 50 mL/min (calculated using the Cockcroft-Gault formula)
- •–Serum albumin = 28 g/L (2.8 g/dL)
- •–For patients not receiving therapeutic anticoagulation: INR <1.25
- •–Urine dipstick for proteinuria < 2+ (within 14 days prior to initiation of study treatment), unless a subsequent 24-hour urine collection demonstrates < 1 g of protein in 24 hours.
- •11.Negative HIV test at screening
- •12.Documented virology status of hepatitis, as confirmed by screening HBV and HCV serology test.
- •For patients with active hepatitis B virus (HBV): HBV DNA < 500 IU/mL obtained within 28 days prior to randomization, and Anti-HBV treatment (per local standard of care) for a minimum of 14 days prior to randomization and willingness to continue treatment for the length of the study
- •13.For females of childbearing potential (FCBP): negative pregnancy test within 14 days before randomization and agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of <1% per year during the treatment period and for at least 5 months after the last dose of atezolizumab or 6 months after the last dose of bevacizumab.
- •A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male partner’s sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.
- •The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
- •14.For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:
- •With female partners of childbearing potential, men must remain abstinent or use
排除标准
- •1.Diffuse HCC or presence of vascular invasion or extrahepatic spread or more than 7 lesions or at least one lesion = 7 cm
- •2. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
- •3. Clin. rel. ascites (defined by protocol)
- •4. Uncontrolled pleural Effusion/ pericardial effusion.
- •5. History or presence of hepatic encephalopathy
- •6. Co-infection of HBV and HCV
- •(History of HCV infection but negative for HCV RNA by PCR are considered non-infected with HCV)
- •7.Patients act. listed for transplantation or not yet listed but potentialy eligible for Transplantation (see protocol)
- •8.Prior systemic therapy for HCC
- •9.Prior treatment with TACE or SIRT
- •10.Prior local ablation treatment (refer to protocol for Detail)
- •11.Any contraindication to TACE
- •12.Major gastrointestinal bleeding within last 4 weeks
- •13.Patients with untreated or incompletely treated varices with bleeding or high-risk for bleeding (please refer to protocol)
- •14.Active or history of autoimmune disease or immune deficiency (described in protocol)
- •15.Prior allogeneic stem cell or solid organ transplantation
- •16.History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening CT scan (more Details in Protocol)
- •17.Active tuberculosis (defined by protocol)
- •18.Severe infection within last 4 weeks
- •19.Significant cardiovascular disease (more Details in protocol)
- •20.History of congenital long QT syndrome or corrected QT interval >500 ms or repeated demonstration of a corrected QT interval >450 ms
- •21.Inadequately controlled arterial hypertension (defined by protocol)
- •22.Significant vascular disease including aortic aneurysm requiring surgical repair or peripheral arterial thrombosis with last 6 months
- •23.History of abdominal or tracheoesophageal fistula or gastrointestinal perforation, or intra-abdominal abscess within last 6 months
- •24.History or clinical signs of gastrointestinal obstruction or requirement for routine parenteral Hydration/nutrition, or tube feeding. Evidence of abdominal free air (not explained by paracentesis/recent surgical procedure)
- •25.History of intra-abdominal inflammatory process within last 6 months
- •26.Evidence of bleeding diathesis or significant coagulopathy
- •27.Any other conditions that contraindicates participation in the sstudy
- •28.Uncontrolled tumor-related pain.
- •29.Severe, non healing or dehisced wound, active ulcer, or untreated bone fracture
- •30.History of malignancy other than HCC (with the exception: please refer to protocol)
- •31.Current or recent use of acetylsalicyclic acid or treatment with dipyramidole, ticlopidine, clopidogrel, and cilostazol
- •32.Current or recent use of full dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purpose(for exeptions please refer to protocol)
- •33.Chronic daily treatment with NSAID. Occasional use of NSAIDs for the symptomatic relief is allowed.
- •34.Treatment with a live, attenuated vaccine within 4 weeks prior to randomization, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the last dose of atezolizumab.
- •35.Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti?CTLA-4, anti?PD-1, and anti?PD-L1 therapeutic antibodies
- •36.Hypersensitivity to atezolizumab, bevacizumab, any of the excipients, known hypersensitivity to CHO cell products or to human or humanized a
研究者
相似试验
进行中（未招募）
1 期
A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR mutationsAdvanced or metastatic untreated EGFR mutation positive NSCLCMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002869-35-ITFONDAZIONE RICERCA TRASLAZIONALE (FORT)189
进行中（未招募）
1 期
A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR mutationsEUCTR2019-002869-35-ESFONDAZIONE RICERCA TRASLAZIONALE (FORT)189
进行中（未招募）
1 期
A Randomized, Double-Blind, Phase II Study Comparing the Anti-Retroviral Safety and Efficacy of Dexelvucitabine (DFC) 200 mg Once Daily to Lamivudine (3TC) 300 mg Once Daily in Addition to Optimized Background Therapy in HIV-1 Infected Subjects Who Have Failed and/or Harbor HIV with Resistance Mutations to NRTIs, PIs, and NNRTIs - DECLARE 1EUCTR2006-000096-16-GBIncyte Corporation250
进行中（未招募）
1 期
Study of Nivolumab in Combination with Ipilimumab compare to nivolumab in combination with Ipilimumab-Placebo in patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckRecurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)MedDRA version: 21.1Level: PTClassification code 10063569Term: Metastatic squamous cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001645-64-BEBristol-Myers Squibb International Corporation675
进行中（未招募）
1 期
Study of Nivolumab in Combination with Ipilimumab compare to nivolumabin combination with Ipilimumab-Placebo in patients with Recurrent orMetastatic Squamous Cell Carcinoma of the Head and NeckRecurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(SCCHN)MedDRA version: 21.1Level: PTClassification code 10063569Term: Metastatic squamous cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001645-64-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO675